These agents have been found to prevent phosphorylation and breakdown of IκBα (a key inhibitory protein) in RA [43, 44, 47] and promote phosphorylation of AMPK in psoriasis (which indirectly prevents p65 nuclear translocation) [45, 48]. Here, NFKBIA is linked to psoriasis.